My clinical and research interests are focused on thoracic oncology and developmental therapeutics as it relates to thoracic oncology. A clinical trial program has been developed that provides a wide range of studies from phase I “first in man” trials to phase III trials. A particular interest has been the development of multimodality studies in collaboration with radiation oncology and thoracic surgery. Of note, clinical trial approaches developed through this program have become national studies in the NCI-sponsored Cancer Cooperative Group program.
A laboratory program has been developed to optimize drug combinations and potential markers of drug activity or resistance with the goal of translating these results into clinical trials. Studies have been conducted with eicosanoid modulators, antitubulin agents (including benzyoylphenylurea and aurora kinase inhibitors) and others. In addition, collaborative efforts have begun with other faculty including Dr. Suzanne Ostrand-Rosenberg at UMBC to develop lung cancer vaccines and Dr. Ricardo Feldman to develop mouse models of EGFR-mutant lung cancer. In addition, I actively collaborate with Dr. Ming Tan of biostatistics on the analysis of preclinical data and the development of novel trial designs.
On a national level, I have been active in the lung cancer committees of both the CALGB and RTOG. Strategies initiated through our local research have been brought to the national stage through these organizations. For example, laboratory studies demonstrating synergy of eicosanoid modulators were developed into a phase I trial at the University of Maryland and ultimately into a national trial in the CALGB. Currently, a trial is in development that will investigate the role of thymidylate synthetase germline polymorphisms and the response to pemetrexed in the CALGB. Through the University of Chicago Consortium, I have been active in developing Phase II trials of novel therapeutics in lung cancer as well.
Edelman MJ, Gandara DR. Promising New Agents in the Treatment of Non-Small Cell Lung Cancer. Cancer Chemother Pharmacol 37:385-393, 1996.
Edelman MJ, Gandara DR, Roach M, Benfield J. Multimodality Therapy in Stage III Non-Small Cell Lung Cancer. Ann Thorac Surg 61:1564-72, 1996.
Gandara DR, Edelman MJ, Crowley JJ, Livingston RB. Phase II Trial of Edatrexate Plus Carboplatin in Metastatic Non-Small Cell Lung Cancer: A Southwest Oncology Group Study. Cancer Chemother Pharmacol 41:75-78, 1997.
Edelman MJ, Siegel D, Meyers F. The Utility of Follow-up Testing After Curative Cancer Therapy: A Critical Review and Economic Analysis. J Gen Intern Med 12:318-331, 1997.
Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F.Phase I Trial of Edatrexate Plus Carboplatin in Advanced Solid Tumors: Amelioration of Dose-Limiting Mucositis by Ice Chip Cryotherapy. Investigational New Drugs 16:69-75, 1998.
Edelman MJ, Gandara DR. Small Cell Lung Cancer Current Status of New Chemotherapeutic Agents. Critical Reviews in Oncology/Hematology 27:211-220, 1998.
Mack PC, Gandara DR, Bowen C, Edelman MJ, Panglieroni T, Schnier JB, Gelman EP, Gumerlock PH. RB Status as a Determinant of Response to UCN-01 in Non-Small Cell Lung Carcinoma. Clinical Cancer Research. 5:2596-2604, 1999.
Edelman MJ, Gandara DR. Sequential Chemotherapy: Rationale and Clinical Trial Design in Advanced Non-Small Cell Carcinoma. Clinical Lung Cancer 1:122-127, 1999.
Edelman MJ, Gandara DR, Meyers FJ, Ishii R, O’Mahony M, Uhrich M, Lauder I, Houston J, Gietzen DW. Serotonergic Blockade in the Treatment of the Cancer Anorexia-Cachexia Syndrome. Cancer 86:684-8, 1999.
Edelman MJ, Quam H, Mullins B. Interactions of Gemcitabine, Carboplatin and Paclitaxel in Molecularly Defined Non-Small Cell Lung Cancer Cell Lines. Cancer Chemo and Pharm 48:141-4, 2001.
Edelman MJ, Gandara DR, Lau D, Lara P, Lauder J, Tracy D. Sequential Combination Chemotherapy in Advanced Non-small Cell Lung Cancer: Carboplatin and Gemcitabine Followed by Paclitaxel Cancer 92: 146-152, 2001.
Edelman MJ, Suntharalingam M, Krasna MJ. Management of Patients Undergoing Multimodality Therapy for Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 4: 45-53, 2003.
Taimur S and Edelman MJ. Current Treatment Options for Brain Metastases in Patients with Non-Small Cell Lung Cancer. Current Treatment Options in Oncology 4: 89-95, 2003.
Edelman MJ, Gandara DR, Israel V, De Santo J, Hausner P, Doyle LA. Cryptophycin 52 in the Treatment of Platinum Resistant Non-small Cell Lung Cancer, Lung Cancer 39:197-199, 2003.
Edelman MJ, Bauer K, Khanwani S, Van Echo D, Karp J. Clinical and Pharmacologic Study of Tributyrin: An Oral Butyrate Prodrug. Cancer Chemotherapy and Pharm 51:439-444, 2003.
Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. Cell Cycle-dependent Potentiation of Cisplatin by UCN-01 in Non-small Cell Lung Carcinoma. Cancer Chemotherapy and Pharmacology 51: 337-348, 2003.
Abdel-Aziz W, Hickey RJ, Edelman M, Malkas LH Effect of Novel Benzoylphenylurea Derivatives on DNA Polymerase Alpha Activity Using the DNA Synthesome Model in vitro Model System. Invest New Drugs. 21: 421-8, 2003.
Edelman MJ, Chansky K, Crowley J, Leigh B, Gaspar L, Livingston R, Gandara D. Phase II (SWOG 9713) Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small Cell Lung Cancer. J Clin Oncol 2004 Jan 1; 22(1): 127-132.
Edelman MJ, Clark J, Chansky K, Albain K, Gandara DR. Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer: Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel (SWOG 9806). Clin Cancer Res 2004 Aug 15;10(16):5418-24.
Edelman MJ, Smith R, Kendall J, Doyle LA, Hausner P, Kalra K, Bedor M, Bisaccia S. Phase II trial of the novel retinoid, bexarotene, and gemcitabine/carboplatin in advanced non-small cell lung cancer 2005, 23:5774-8. J Clin Oncol
Edelman MJ. The role of bortezomib in chemoradiotherapy of non-small cell lung cancer. Clin Lung Ca 2005, 7 suppl 2: S64-S66.
Bellil Y and Edelman MJ. Bronchogenic carcinoma in solid organ transplant recipients. Current Treatment Options in Oncology. 2006, 7:77-81.
Edelman MJ. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer, Sem Oncol 32 (suppl 10):S3-S8, 2006.
Edelman MJ, Sekine I, Tamura T, Saijo N. Geographic Variation in the Second Line Treatment of Non-small-Cell Lung Cancer. Sem Oncol (in press, 2006)